Lynx1 Capital Management LP
Long book
$632.7M
Q1 2026
Positions
23
Top-10 weight
97%
concentration
Last quarter
+33.3%
SPY +14.8%
Turnover
33%
of book per quarter
Strategy in plain words
auto-generated from filingsLynx1 Capital Management LP is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $632.7M US long book across 23 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: STOKE THERAPEUTICS INC, GH RESEARCH PLC, CULLINAN THERAPEUTICS INC, AGIOS PHARMACEUTICALS INC, DENALI THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 0.2pp per quarter behind the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-22.0%
Q2 2024
-12.0%
Q3 2024
-18.3%
Q4 2024
-23.0%
Q1 2025
+14.6%
Q2 2025
+35.9%
Q3 2025
+17.4%
Q4 2025
+12.8%
Q1 2026
+33.3%
Sector allocation
Healthcare 100%
Long book by quarter
What does Lynx1 Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| STOK STOKE THERAPEUTICS INC | Healthcare | 4.8M | $155.1M | 24.5% | -11.9% |
| GHRS GH RESEARCH PLC | Healthcare | 10.8M | $151.3M | 23.9% | +3.4% |
| CGEM CULLINAN THERAPEUTICS INC | Healthcare | 9.0M | $127.4M | 20.1% | Held |
| AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 2.6M | $88.3M | 14.0% | +3179.9% |
| DNLI DENALI THERAPEUTICS INC | Healthcare | 1.9M | $36.1M | 5.7% | +8.1% |
| CCCC C4 THERAPEUTICS INC | Healthcare | 7.0M | $18.4M | 2.9% | -1.4% |
| KRRO KORRO BIO INC | Healthcare | 1.5M | $17.4M | 2.8% | +126.9% |
| TCRX TSCAN THERAPEUTICS INC | Healthcare | 8.0M | $8.1M | 1.3% | Held |
| XNCR XENCOR INC | Healthcare | 536.4K | $6.5M | 1.0% | -24.0% |
| DTIL PRECISION BIOSCIENCES INC | Healthcare | 985.1K | $5.4M | 0.9% | -0.9% |
| PASG PASSAGE BIO INC | Healthcare | 623.7K | $4.9M | 0.8% | Held |
| NEUP NEUPHORIA THERAPEUTICS INC | Healthcare | 875.3K | $3.6M | 0.6% | 0.0% |
| TRDA ENTRADA THERAPEUTICS INC | Healthcare | 211.7K | $2.7M | 0.4% | +309.5% |
| CGON CG ONCOLOGY INC | Healthcare | 31.6K | $2.1M | 0.3% | Held |
| IMTX IMMATICS NV | Healthcare | 217.0K | $2.1M | 0.3% | -76.5% |
| DSGN DESIGN THERAPEUTICS INC | Healthcare | 119.5K | $1.3M | 0.2% | +71.9% |
| VYNE VYNE THERAPEUTICS INC | Healthcare | 1.6M | $973K | 0.2% | New |
| HOWL WEREWOLF THERAPEUTICS INC | Healthcare | 657.8K | $548K | 0.1% | +0.3% |
| IBIO IBIO INC | Healthcare | 68.1K | $129K | 0.0% | New |
| BOLT BOLT BIOTHERAPEUTICS INC | Healthcare | 30.8K | $124K | 0.0% | New |
| PRQR PROQR THERAPEUTICS NV | Healthcare | 68.5K | $111K | 0.0% | Held |
| ABSI ABSCI CORP | Healthcare | 21.2K | $64K | 0.0% | New |
| TRAW TRAWS PHARMA INC | Healthcare | 15.1K | $28K | 0.0% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 4, 2026 | 23 | $632.7M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 22 | $494.0M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 13, 2025 | 14 | $491.3M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 15 | $346.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 14 | $279.2M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 18 | $266.7M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 18 | $282.2M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR/ANEW HOLDINGS | Aug 19, 2024 | 1 | $1.3M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 17 | $275.9M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR/ANEW HOLDINGS | May 30, 2024 | 1 | $2.4M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 15 | $385.8M | canonical | SEC ↗ |